Tag: Transthyretin stabilizer

In transthyretin-mediated amyloidosis (ATTR), a progressive and often fatal disease, the transthyretin (TTR) protein misfolds and forms harmful amyloid deposits. The therapeutic effectiveness of Vyndaqel hinges on its unique ability to disrupt this process, making understanding what is the mechanism of action of Vyndaqel crucial for both patients and clinicians.

In November 2024, the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis) to treat adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This oral medication serves a crucial role in reducing death and hospitalizations related to heart problems caused by this rare and serious condition. If you're asking, **'What is Attruby for?'**, this guide will explain its purpose, function, and other important information for patients.